BioNTech is a German biotechnology company primarily known for its work in developing immunotherapies and vaccines, especially in the field of personalized medicine. Founded in 2008, the company gained significant recognition for its collaboration with Pfizer to develop one of the first effective mRNA vaccines against COVID-19, known as BNT162b2 or Comirnaty. BioNTech’s focus is on using messenger RNA (mRNA) technology to create treatments for various diseases, including cancer and infectious diseases. The company’s approach involves harnessing the body’s immune system to generate a targeted response against specific pathogens or tumor cells.
BioNTech is experiencing a financial transition as it shifts focus from COVID-19 vaccines to pioneering mRNA-based cancer therapies. The company reported reduced earnings, with profits per share at €1.08 in…